Zenotech Laboratories Ltd
Incorporated in 1989, Zenotech Laboratories Ltd is in the business of manufacturing biotechnology products[1]
- Market Cap ₹ 338 Cr.
- Current Price ₹ 55.4
- High / Low ₹ 108 / 51.0
- Stock P/E 73.6
- Book Value ₹ 15.8
- Dividend Yield 0.00 %
- ROCE 9.40 %
- ROE 4.93 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 3.52 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 10.6% over past five years.
- Company has a low return on equity of 9.56% over last 3 years.
- Debtor days have increased from 40.3 to 63.2 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2.75 | 4.08 | 2.06 | 2.25 | 11.14 | 13.03 | 26.02 | 22.45 | 36.57 | 42.42 | 40.83 | 43.05 | |
19.75 | 24.14 | 9.73 | 12.65 | 19.01 | 16.54 | 17.04 | 16.07 | 19.11 | 21.71 | 23.56 | 28.87 | |
Operating Profit | -17.00 | -20.06 | -7.67 | -10.40 | -7.87 | -3.51 | 8.98 | 6.38 | 17.46 | 20.71 | 17.27 | 14.18 |
OPM % | -618.18% | -491.67% | -372.33% | -462.22% | -70.65% | -26.94% | 34.51% | 28.42% | 47.74% | 48.82% | 42.30% | 32.94% |
2.39 | 0.35 | 0.04 | 1.91 | 2.37 | 4.71 | 7.54 | 0.41 | 0.63 | 1.08 | 0.96 | 3.47 | |
Interest | 4.69 | 6.65 | 7.55 | 7.50 | 2.45 | 0.12 | 0.89 | 1.55 | 1.22 | 0.11 | 0.00 | 0.00 |
Depreciation | 3.56 | 4.06 | 3.96 | 3.87 | 3.90 | 4.20 | 4.85 | 6.46 | 6.97 | 7.17 | 7.09 | 6.96 |
Profit before tax | -22.86 | -30.42 | -19.14 | -19.86 | -11.85 | -3.12 | 10.78 | -1.22 | 9.90 | 14.51 | 11.14 | 10.69 |
Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -123.94% | 20.12% | 25.49% | 47.52% |
-22.86 | -30.41 | -19.14 | -19.87 | -11.85 | -3.13 | 10.78 | -1.22 | 22.18 | 11.59 | 8.30 | 5.61 | |
EPS in Rs | -3.75 | -4.99 | -3.14 | -3.26 | -1.94 | -0.51 | 1.77 | -0.20 | 3.63 | 1.90 | 1.36 | 0.92 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 27% |
5 Years: | 11% |
3 Years: | 6% |
TTM: | 5% |
Compounded Profit Growth | |
---|---|
10 Years: | 8% |
5 Years: | 1% |
3 Years: | -41% |
TTM: | -45% |
Stock Price CAGR | |
---|---|
10 Years: | 0% |
5 Years: | 21% |
3 Years: | -4% |
1 Year: | -19% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 12% |
3 Years: | 10% |
Last Year: | 5% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 34.43 | 34.43 | 34.43 | 34.43 | 61.03 | 61.03 | 61.03 | 61.03 | 61.03 | 61.03 | 61.03 | 61.03 |
Reserves | -31.17 | -61.68 | -80.49 | -100.33 | -19.01 | -22.13 | -11.40 | -12.62 | 9.61 | 21.24 | 29.51 | 35.10 |
46.92 | 54.32 | 54.29 | 54.28 | 0.00 | 20.24 | 21.42 | 20.66 | 6.00 | 0.00 | 0.00 | 0.00 | |
20.01 | 36.64 | 44.69 | 62.37 | 39.72 | 25.45 | 14.51 | 16.78 | 17.45 | 18.61 | 15.66 | 14.90 | |
Total Liabilities | 70.19 | 63.71 | 52.92 | 50.75 | 81.74 | 84.59 | 85.56 | 85.85 | 94.09 | 100.88 | 106.20 | 111.03 |
56.25 | 52.13 | 48.17 | 46.83 | 44.43 | 43.11 | 48.73 | 74.23 | 70.91 | 65.38 | 65.58 | 60.87 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 2.32 | 16.95 | 29.08 | 2.18 | 0.28 | 4.98 | 1.96 | 3.57 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
13.94 | 11.58 | 4.75 | 3.92 | 34.99 | 24.53 | 7.75 | 9.44 | 22.90 | 30.52 | 38.66 | 46.59 | |
Total Assets | 70.19 | 63.71 | 52.92 | 50.75 | 81.74 | 84.59 | 85.56 | 85.85 | 94.09 | 100.88 | 106.20 | 111.03 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-24.30 | -7.72 | -4.80 | 1.64 | -16.25 | -14.04 | 11.38 | 5.74 | 17.67 | 20.66 | 11.82 | 9.49 | |
-0.50 | 0.34 | 5.50 | -0.69 | -2.65 | -16.19 | -20.79 | -4.82 | -1.84 | -5.82 | -21.15 | 15.29 | |
29.63 | 6.77 | -0.83 | -0.72 | 46.83 | 15.02 | -2.70 | 0.45 | -15.87 | -6.11 | 0.00 | 0.00 | |
Net Cash Flow | 4.83 | -0.60 | -0.13 | 0.23 | 27.92 | -15.21 | -12.11 | 1.38 | -0.04 | 8.73 | -9.33 | 24.78 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 11.95 | 35.78 | 62.01 | 0.00 | 0.00 | 66.11 | 26.09 | 61.78 | 39.22 | 28.57 | 29.05 | 63.16 |
Inventory Days | 562.10 | 232.69 | 305.45 | 202.29 | 374.12 | 294.03 | ||||||
Days Payable | 487.64 | 222.42 | 816.45 | 1,127.98 | 2,468.31 | 2,088.61 | ||||||
Cash Conversion Cycle | 86.41 | 46.05 | -448.99 | -925.69 | -2,094.19 | -1,728.47 | 26.09 | 61.78 | 39.22 | 28.57 | 29.05 | 63.16 |
Working Capital Days | -2,416.96 | -3,294.84 | -8,061.89 | -10,395.20 | -1,218.52 | -537.00 | -171.00 | -163.56 | -106.00 | -98.86 | -62.93 | -27.98 |
ROCE % | -39.28% | -61.54% | -65.67% | -61.84% | -5.93% | 8.14% | 0.47% | 15.26% | 18.35% | 12.94% | 9.40% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
27 Apr - Copies of extracts of Standalone Financial Results of the Company for the quarter and financial year ended March 31, 2025 in Financial Express (English Newspaper) …
-
Integrated Filing (Financial)
26 Apr - Audited FY25 financial results with profit of Rs 561.29L, unmodified audit opinion, and related party transactions disclosed.
- Audited Financial Results For The Quarter And Financial Year Ended March 31, 2025 25 Apr
-
Board Meeting Outcome for Audited Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2025
25 Apr - Zenotech reports audited standalone financial results for FY ended March 31, 2025 with clean audit opinion.
-
Board Meeting Intimation for Considering And Approving Audited Standalone Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2025.
21 Apr - Board meeting on April 25 to approve FY25 audited results; trading window closed April 1-27.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
ZTLL is a part of Sun Pharmaceuticals Industries Ltd. It does manufacturing and marketing of pharmaceuticals and bio-pharmaceutical products. It is a pharmaceutical specialty
generic injectables company engaged in the area of manufacturing Oncology, bio-technology and General Injectables products